Methods of treatment using bempedoic acid
US-2024226049-A1 · Jul 11, 2024 · US
Benzimidazoles and indoles as taro inhibitors
US11141403B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11141403-B2 |
| Application number | US-201616061481-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 13, 2016 |
| Priority date | Dec 16, 2015 |
| Publication date | Oct 12, 2021 |
| Grant date | Oct 12, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a bacterial infection in a patient by administering to a patient in need thereof, a synergistic combination of a TarO inhibitor compound or a pharmaceutically acceptable salt thereof, and a β-lactam antibiotic; wherein the bacterial infection is a methicillin-resistant S. aureus infection or a methicillin-resistant S. epidermidis infection; wherein the β-lactam antibiotic is imipenem, dicloxacillin, cephalexin, or tebipenem, wherein the TarO inhibitor compound is selected from:
Assignees
Inventors
Classifications
directly linked by a ring-member-to-ring-member bond · CPC title
linked by a carbon chain containing aromatic rings · CPC title
condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine · CPC title
- A61K31/397Primary
having four-membered rings, e.g. azetidine · CPC title
with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11141403B2 cover?
- Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic.
- Who is the assignee on this patent?
- Merck Sharp & Dohme, Caldwell John P, Ho Ginny Dai, and 15 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/397. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).